Popular Research Topics by Year

• angiogenesis inhibitor
• antineoplastic agent
• cancer
• cancer combination chemotherapy
• cancer immunotherapy
• checkpoint inhibitor
• chemotherapy
• clinical trial (topic)
• colorectal cancer
• cytotoxic t lymphocyte antigen 4 antibody
• drug combination
• french clinical practice guidelines
• guidelines
• hepatocellular carcinoma
• human
• immune checkpoint inhibitor
• immunology
• liver cell carcinoma
• metastatic hepatic metastases surgery
• molecularly targeted therapy
• mtor inhibitors
• priority journal
• prognosis
• programmed cell death 1 antibody
• programmed cell death ligand 1 antibody

• atezolizumab
• avelumab
• bevacizumab
• cancer immunotherapy
• colon cancer
• colorectal cancer
• disease free survival
• drug efficacy
• durvalumab
• gene
• human
• ipilimumab
• microsatellite instability
• nivolumab
• overall survival
• oxaliplatin
• pembrolizumab
• pole gene
• priority journal
• progression free survival
• regorafenib
• review
• somatic mutation
• ticilimumab
• toripalimab

• ace2
• acquired-resistance
• adjuvant chemotherapy
• adolescent
• adult
• advanced cancer
• aged
• aged, 80 and over
• antibodies, monoclonal, humanized
• antineoplastic agents, immunological
• article
• beta(2)-microglobulin
• breast tumor
• cancer
• cancer adjuvant therapy
• cancer patient
• cancer staging
• capecitabine
• capox
• cgas
• checkpoint blockade
• colorectal neoplasms
• human
• major clinical study
• mismatch repair

• adult
• adverse event
• antineoplastic agent
• antineoplastic combined chemotherapy protocols
• article
• cancer patient
• cancer staging
• clinical trial
• colorectal cancer
• colorectal neoplasms
• colorectal tumor
• controlled study
• dna mismatch repair
• dna replication
• female
• genetics
• human
• humans
• immunotherapy
• major clinical study
• male
• mismatch repair
• mutation
• neoplasm
• neoplasms